Justin Stebbing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2930229/publications.pdf

Version: 2024-02-01

227 papers	9,464 citations	66250 44 h-index	51423 90 g-index
243 all docs	243 docs citations	243 times ranked	18360 citing authors

#	Article	IF	Citations
1	Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet, The, 2020, 395, e30-e31.	6.3	1,147
2	COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infectious Diseases, The, 2020, 20, 400-402.	4.6	915
3	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2014, 15, 406-414.	5.1	703
4	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 338-346.	1.8	299
5	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research, 2019, 25, 4255-4263.	3.2	281
6	Mechanism of baricitinib supports artificial intelligenceâ€predicted testing in <scp>COVID</scp> â€19 patients. EMBO Molecular Medicine, 2020, 12, e12697.	3.3	229
7	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 2019, 134, 39-45.	2.0	200
8	Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clinical Cancer Research, 2017, 23, 88-96.	3.2	186
9	A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis. Journal of Clinical Gastroenterology, 2010, 44, 214-219.	1.1	185
10	JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Science Advances, 2021, 7, .	4.7	176
11	Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptorâ€“Positive Metastatic Breast Cancer. Clinical Chemistry, 2015, 61, 974-982.	1.5	155
12	Patientâ€derived xenografts for individualized care in advanced sarcoma. Cancer, 2014, 120, 2006-2015.	2.0	154
13	Clinical Characteristics and Outcomes of COVID-19â€“Infected Cancer Patients: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 371-380.	3.0	153
14	Endocrine Resistance in Hormone Receptor Positive Breast Cancerâ€“From Mechanism to Therapy. Frontiers in Endocrinology, 2019, 10, 245.	1.5	150
15	MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. Gastroenterology, 2014, 146, 268-277.e18.	0.6	141
16	Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. Journal of Allergy and Clinical Immunology, 2021, 147, 107-111.	1.5	140
17	Where Does HIV Live?. New England Journal of Medicine, 2004, 350, 1872-1880.	13.9	137
18	The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer, 2009, 63, 94-97.	0.9	134

#	Article	IF	Citations
19	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nature Medicine, 2011, 17, 715-719.	15.2	118
20	Is asthma protective against COVIDâ€19?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 866-868.	2.7	117
21	Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Oncotarget, 2018, 9, 19006-19013.	0.8	116
22	SARS-CoV-2 (COVID-19) superspreader events. Journal of Infection, 2021, 82, 36-40.	1.7	114
23	TGF-Î² induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Nature Communications, 2018, 9, 1845.	5.8	101
24	miRâ€515â€5p controls cancer cell migration through <scp>MARK</scp> 4 regulation. EMBO Reports, 2016, 17, 570-584.	2.0	97
25	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. European Journal of Cancer, 2015, 51, 1389-1404.	1.3	94
26	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncology, The, 2017, 18, 917-928.	5.1	93
27	Mammosphere Formation Assay from Human Breast Cancer Tissues and Cell Lines. Journal of Visualized Experiments, 2015, , .	0.2	89
28	Kinases as targets in the treatment of solid tumors. Cellular Signalling, 2010, 22, 984-1002.	1.7	88
29	HIVâ€associated multicentric Castleman's disease. American Journal of Hematology, 2008, 83, 498-503.	2.0	74
30	Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. Communications Biology, 2019, 2, 315.	2.0	71
31	Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood, 2011, 118, 271-275.	0.6	69
32	Immunogenicity of the <scp>BNT162b2</scp> vaccine in frail or disabled nursing home residents: <scp>COVIDâ€A</scp> study. Journal of the American Geriatrics Society, 2021, 69, 1441-1447.	1.3	69
33	Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma. Molecular Cancer, 2018, 17, 132.	7.9	67
34	Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours. Journal of Controlled Release, 2018, 280, 87-98.	4.8	66
35	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. OncoImmunology, 2016, 5, e1213934.	2.1	65
36	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. OncoImmunology, 2018, 7, e1396403.	2.1	60

#	Article	IF	Citations
37	Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. British Journal of Cancer, 2016, 115, 789-796.	2.9	56
38	Baricitinib for COVID-19: a suitable treatment? â€“ Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 1013-1014.	4.6	55
39	The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1â€“infected â€œtrueâ€•long-term nonprogressors. Blood, 2003, 101, 4000-4004.	0.6	54
40	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Lancet, The, 2015, 385, S37.	6.3	54
41	Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets. PLoS ONE, 2014, 9, e90948.	1.1	53
42	TP53 regulates miRNA association with AGO2 to remodel the miRNAâ€“mRNA interaction network. Genome Research, 2016, 26, 331-341.	2.4	51
43	Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 275-281.	0.6	47
44	Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood, 2003, 102, 1806-1814.	0.6	45
45	Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer, 2007, 109, 93-99.	2.0	45
46	The germline of the malaria mosquito produces abundant miRNAs, endo-siRNAs, piRNAs and 29-nt small RNAs. BMC Genomics, 2015, 16, 100.	1.2	44
47	Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Research, 2014, 34, 1531-5.	0.5	44
48	A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opinion on Drug Safety, 2020, 19, 1505-1511.	1.0	39
49	A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers. Frontiers in Immunology, 2021, 12, 762598.	2.2	39
50	CNS penetration of potential anti-COVID-19 drugs. Journal of Neurology, 2020, 267, 1880-1882.	1.8	37
51	Hepatitis C Virus Infection in HIV Type 1–Infected Individuals Does Not Accelerate a Decrease in the CD4+ Cell Count but Does Increase the Likelihood of AIDS-Defining Events. Clinical Infectious Diseases, 2005, 41, 906-911.	2.9	35
52	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Research and Treatment, 2012, 132, 537-544.	1.1	35
53	A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. OncoImmunology, 2020, 9, 1781333.	2.1	34
54	The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. International Journal of Cancer, 2004, 108, 631-633.	2.3	33

#	Article	IF	Citations
55	PIK3CÎ´ expression by fibroblasts promotes triple-negative breast cancer progression. Journal of Clinical Investigation, 2020, 130, 3188-3204.	3.9	33
56	The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study. PLoS ONE, 2013, 8, e62543.	1.1	32
57	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin Î² ₁. Science Signaling, 2014, 7, ra58.	1.6	32
58	A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemotherapy and Pharmacology, 2018, 81, 505-514.	1.1	32
59	LMTK3 confers chemo-resistance in breast cancer. Oncogene, 2018, 37, 3113-3130.	2.6	31
60	Gene of the month: Axl. Journal of Clinical Pathology, 2016, 69, 391-397.	1.0	30
61	LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. Cancer Letters, 2016, 372, 137-146.	3.2	30
62	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859.	2.6	29
63	Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. International Journal of Cancer, 2004, 108, 473-474.	2.3	28
64	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 1349-1351.	5.2	28
65	A novel platform for attenuating immune hyperactivity using <scp>EXOâ€CD24</scp> in COVIDâ€19 and beyond. EMBO Molecular Medicine, 2022, 14, .	3.3	27
66	MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma. PLoS ONE, 2014, 9, e85935.	1.1	26
67	Baricitinib reduces 30â€day mortality in older adults with moderateâ€toâ€severe <scp>COVID</scp>â€19 pneumonia. Journal of the American Geriatrics Society, 2021, 69, 2752-2758.	1.3	25
68	The Tumor-Suppressor Protein OPCML Potentiates Antiâ€“EGFR- and Antiâ€“HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 2246-2256.	1.9	24
69	Milk thistle: early seeds of potential. Lancet Oncology, The, 2013, 14, 929-930.	5.1	23
70	The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNAâ€“mRNA interaction network. Lancet, The, 2015, 385, S15.	6.3	23
71	Circulating free DNA in the management of breast cancer. Annals of Translational Medicine, 2014, 2, 3.	0.7	23
72	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Journal of the National Cancer Institute, 2021, 113, 443-452.	3.0	22

#	Article	IF	Citations
73	New insights into the immunology and evolution of HIV. Cell Research, 2003, 13, 1-7.	5.7	21
74	Paclitaxel for AIDS-associated Kaposiâ€™s sarcoma. Expert Review of Anticancer Therapy, 2005, 5, 215-219.	1.1	21
75	LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. Cell Reports, 2015, 12, 837-849.	2.9	21
76	The relationship between ethnicity, social deprivation and late presentation of colorectal cancer. Cancer Epidemiology, 2017, 47, 88-93.	0.8	21
77	ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. Oncotarget, 2016, 7, 27599-27612.	0.8	21
78	Hyperthermia in cancer: is it coming of age?. Lancet Oncology, The, 2014, 15, 565-566.	5.1	20
79	Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors. Annals of Surgery, 2021, 274, e1-e9.	2.1	20
80	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. Molecular Cancer Therapeutics, 2013, 12, 2261-2272.	1.9	19
81	Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.2	19
82	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. Journal of Clinical Oncology, 2020, 38, 1070-1080.	0.8	19
83	EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes. Frontiers in Oncology, 2021, 11, 680804.	1.3	19
84	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget, 2016, 7, 28556-28569.	0.8	19
85	Antibody-targeted MHC complexâ€“directed expansion of HIV-1â€“ and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination. Blood, 2004, 103, 1791-1795.	0.6	18
86	The structure-function relationship of oncogenic LMTK3. Science Advances, 2020, 6, .	4.7	18
87	SCIRT lncRNA Restrains Tumorigenesis by Opposing Transcriptional Programs of Tumor-Initiating Cells. Cancer Research, 2021, 81, 580-593.	0.4	18
88	Non-Hodgkinâ€™s lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals. Expert Review of Anticancer Therapy, 2006, 6, 335-341.	1.1	17
89	Primary Esophageal Carcinoma in the Era of Highly Active Antiretroviral Therapy. Archives of Internal Medicine, 2010, 170, 203.	4.3	17
90	Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics. Molecular and Cellular Proteomics, 2015, 14, 2479-2492.	2.5	17

#	Article	IF	Citations
91	Antioxidants and cancer. Lancet Oncology, The, 2011, 12, 996.	5.1	16
92	Human NK Cells Develop an Exhaustion Phenotype During Polar Degranulation at the Aspergillus fumigatus Hyphal Synapse. Frontiers in Immunology, 2018, 9, 2344.	2.2	16
93	Managing patients with cancer in the COVID-19 era. European Journal of Cancer, 2020, 132, 5-7.	1.3	16
94	A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). Journal of Antimicrobial Chemotherapy, 2004, 53, 501-505.	1.3	15
95	Whole Genome Sequence Analysis Suggests Intratumoral Heterogeneity in Dissemination of Breast Cancer to Lymph Nodes. PLoS ONE, 2014, 9, e115346.	1.1	15
96	Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors. Cell Reports, 2017, 18, 1687-1698.	2.9	15
97	Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR. Nucleic Acids Research, 2017, 45, gkx022.	6.5	15
98	The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 165372.	1.8	15
99	JAK Inhibitors â€" More Than Just Glucocorticoids. New England Journal of Medicine, 2021, 385, 463-465.	13.9	15
100	Targeting ALK Rearrangements in NSCLC: Current State of the Art. Frontiers in Oncology, 2022, 12, 863461.	1.3	15
101	The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. Cancer, 2008, 113, 1489-1495.	2.0	14
102	PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling. Oncogene, 2022, 41, 2749-2763.	2.6	14
103	All for CD91 and CD91 for all. Journal of Antimicrobial Chemotherapy, 2003, 53, 1-3.	1.3	13
104	Ginger: the root of cancer therapy?. Lancet Oncology, The, 2012, 13, 235-236.	5.1	13
105	Gene of the month: NANOG. Journal of Clinical Pathology, 2015, 68, 763-765.	1.0	13
106	Noncoding RNAs and the control of signalling via nuclear receptor regulation in health and disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 529-543.	2.2	13
107	Melatonin: resetting the clock of cancer progression?. Lancet Oncology, The, 2016, 17, 23-24.	5.1	13
108	Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 754768.	1.3	13

#	Article	IF	Citations
109	An overview of drug development for metastatic breast cancer. British Journal of Nursing, 2012, 21, S18-S22.	0.3	12
110	Black cohosh, hot flushes, and breast cancer. Lancet Oncology, The, 2015, 16, 137-138.	5.1	12
111	Geographic Variation in EGFR Mutation Frequency inÂLung Adenocarcinoma May Be Explained by Interethnic Genetic Variation. Journal of Thoracic Oncology, 2018, 13, 454-458.	0.5	12
112	Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury. Cell Reports Medicine, 2020, 1, 100145.	3.3	12
113	Immunotherapy-Related Cystitis: Case Report and Review of the Literature. OncoTargets and Therapy, 2021, Volume 14, 4321-4328.	1.0	12
114	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO Precision Oncology, 2021, 5, 1768-1776.	1.5	12
115	Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Research and Treatment, 2021, 188, 631-640.	1.1	11
116	Prognostic Significance of Immune Subset Measurement in Individuals With AIDS-Associated Kaposi's Sarcoma. Journal of Clinical Oncology, 2007, 25, 2230-2235.	0.8	10
117	Thermosensitive Liposome-Mediated Drug Delivery in Chemotherapy: Mathematical Modelling for Spatioâ€“temporal Drug Distribution and Model-Based Optimisation. Pharmaceutics, 2019, 11, 637.	2.0	10
118	Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals. Annals of the Rheumatic Diseases, 2021, 80, 1245-1246.	0.5	10
119	Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).. Journal of Clinical Oncology, 2017, 35, 510-510.	0.8	10
120	Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?. Oncotarget, 2018, 9, 9456-9467.	0.8	10
121	Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients. Cell Research, 2004, 14, 251-256.	5.7	9
122	Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1155-1162.	1.5	9
123	Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. Future Oncology, 2018, 14, 1909-1919.	1.1	9
124	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. Frontiers in Oncology, 2020, 10, 549168.	1.3	9
125	Novel immunotherapeutic drugs for the treatment of lung cancer. Current Opinion in Oncology, 2022, 34, 89-94.	1.1	9
126	Immunogenicity after 6â€‰months of <scp>BNT162b2</scp> vaccination in frail or disabled nursing home residents: The <scp>COVIDâ€A</scp> Study. Journal of the American Geriatrics Society, 2022, 70, 650-658.	1.3	9

#	Article	IF	Citations
127	Kaposi's sarcoma as a model for cancer immunotherapy. Trends in Molecular Medicine, 2004, 10, 187-193.	3.5	8
128	Chocolate: delicious beauty or harmful beast?. Lancet Oncology, The, 2013, 14, 457-458.	5.1	8
129	Aloe vera, a natural cancer soother?. Lancet Oncology, The, 2016, 17, 421.	5.1	8
130	Single-cell sequencing in cancer research. Expert Review of Molecular Diagnostics, 2016, 16, 1-5.	1.5	8
131	A cell-cycle signature classifier for pan-cancer analysis. Oncogene, 2020, 39, 6041-6042.	2.6	8
132	What is the intermediate host species of SARS-CoV-2?. Future Virology, 2021, 16, 153-156.	0.9	8
133	Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. Aids, 2003, 17, 1998-2000.	1.0	8
134	The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. Vaccines, 2022, 10, 951.	2.1	8
135	Cardiotoxicity and anthracyclines. Breast Cancer Research and Treatment, 2008, 107, 451-453.	1.1	7
136	No evidence for a polyomavirus association or aetiology in AIDS-associated nonsmall cell lung cancer. Aids, 2010, 24, 1221-1223.	1.0	7
137	Cannabis and cancer: reality or pipe dream?. Lancet Oncology, The, 2015, 16, 1291-1292.	5.1	7
138	Garlic: a stake through the heart of cancer?. Lancet Oncology, The, 2016, 17, 879-880.	5.1	7
139	Strategies in functional proteomics: Unveiling the pathways to precision oncology. Cancer Letters, 2016, 382, 86-94.	3.2	7
140	Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. Aids, 2007, 21, 1826-1828.	1.0	6
141	Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments. Cancer, 2008, 112, 955-961.	2.0	6
142	Use of Antidepressants and Risk of Cancer in Individuals Infected With HIV. Journal of Clinical Oncology, 2008, 26, 2305-2310.	0.8	6
143	Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer. Breast Cancer Research and Treatment, 2010, 124, 543-549.	1.1	6
144	SSB1/SSB2 Proteins Safeguard B Cell Development by Protecting the Genomes of B Cell Precursors. Journal of Immunology, 2019, 202, 3423-3433.	0.4	6

#	Article	IF	Citations
145	LMTK3 inhibition affects microtubule stability. Molecular Cancer, 2021, 20, 53.	7.9	6
146	First-Line Treatment Options for PD-L1â€“Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 657545.	1.3	6
147	LMTK3 polymorphism in patients with metastatic colon cancer.. Journal of Clinical Oncology, 2012, 30, 471-471.	0.8	6
148	Identification of an immune gene-associated prognostic signature in patients with bladder cancer. Cancer Gene Therapy, 2022, 29, 494-504.	2.2	6
149	Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk. Journal of Clinical Pathology, 2011, 64, 829-831.	1.0	5
150	The need for multidisciplinarity in specialist training to optimize future patient care. Nature Reviews Clinical Oncology, 2017, 14, 508-517.	12.5	5
151	Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer. Expert Review of Anticancer Therapy, 2018, 18, 531-541.	1.1	5
152	What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials. Med, 2020, 1, 9-10.	2.2	5
153	The Emergence of Baricitinib: A Story of Tortoises Versus Hares. Clinical Infectious Diseases, 2021, 72, 1251-1252.	2.9	5
154	The Rationale and Development of New Drugs to Treat HIV Infection. Medicinal Chemistry, 2005, 1, 635-642.	0.7	5
155	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. Oncologist, 2022, 27, e561-e570.	1.9	5
156	Baricitinib as the treatment of choice for hospitalised individuals with COVID-19. EClinicalMedicine, 2022, 49, 101493.	3.2	5
157	Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. Oncotarget, 2018, 9, 17589-17596.	0.8	4
158	Sports balls as potential SARS-CoV-2 transmission vectors. Public Health in Practice, 2020, 1, 100029.	0.7	4
159	Asthma phenotypes, comorbidities, and disease activity in COVIDâ€19: The need of risk stratification. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 955-956.	2.7	4
160	Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC. OncoTargets and Therapy, 2021, Volume 14, 3409-3415.	1.0	4
161	Spatially resolved profiling of colorectal cancer lipid biochemistry via DESI imaging mass spectrometry to reveal morphology-dependent alterations in fatty acid metabolism.. Journal of Clinical Oncology, 2016, 34, e15104-e15104.	0.8	4
162	Reply to S.E. Krown et al. Journal of Clinical Oncology, 2014, 32, 2514-2515.	0.8	3

#	Article	IF	Citations
163	Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer. Data in Brief, 2016, 7, 740-746.	0.5	3
164	The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e217-e223.	0.9	3
165	Lessons to Europe from China for cancer treatment during the COVID-19 pandemic. British Journal of Cancer, 2020, 123, 7-8.	2.9	3
166	<scp>COVID</scp>â€19 and the risk to cancer patients in China. International Journal of Cancer, 2021, 148, 265-266.	2.3	3
167	Reducing transmission of SARS-CoV-2 with intranasal prophylaxis. EBioMedicine, 2021, 63, 103170.	2.7	3
168	805â€...Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours. , 2020, 8, A854-A854.		3
169	Programmed cell death (PD-1) ligands expression in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs): relationship with angiogenesis and clinical outcome.. Journal of Clinical Oncology, 2016, 34, e15658-e15658.	0.8	3
170	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of â€œindolentâ€•stage IV disease (Stage IV_{indolent}).. Journal of Clinical Oncology, 2018, 36, 1019-1019.	0.8	3
171	Association of gender-related tumor recurrence with a polymorphic variant of LMTK3 in stage II and III colon cancer.. Journal of Clinical Oncology, 2012, 30, 454-454.	0.8	3
172	Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis. Oncology Research and Treatment, 2022, 45, 281-290.	0.8	3
173	The antiâ€tumor effects of human immunodeficiency virus protease inhibitors: Ready for real time?. International Journal of Cancer, 2011, 128, 1-2.	2.3	2
174	Uncaria tomentosa, the cat's whiskers or claws?. Lancet Oncology, The, 2014, 15, 1299-1300.	5.1	2
175	Electrotherapy: enlightening modern medicine. Lancet Oncology, The, 2014, 15, 1060-1061.	5.1	2
176	Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis. American Journal of Gastroenterology, 2015, 110, 768-769.	0.2	2
177	Turmeric: a spice for life?. Lancet Oncology, The, 2016, 17, 1639.	5.1	2
178	Pharmacokinetics of CT-P6 and reference trastuzumab by clinical factors in patients with HER2 positive early-stage breast cancer (EBC).. Journal of Clinical Oncology, 2018, 36, 591-591.	0.8	2
179	The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas. Oncotarget, 2018, 9, 11371-11376.	0.8	2
180	Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments. Oncotarget, 2018, 9, 12805-12811.	0.8	2

#	Article	IF	Citations
181	Alternative splicing events in tumor immune infiltration in renal clear cell carcinomas. Cancer Gene Therapy, 2022, 29, 1418-1428.	2.2	2
182	A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 778637.	1.3	2
183	Opposing roles of dendritic cell subsets in HIV-1 infection. Blood, 2006, 108, 1785-1786.	0.6	1
184	Reply to Z.S. Lalmahomed et al. Journal of Clinical Oncology, 2010, 28, e290-e290.	0.8	1
185	Cancer: Where were we, where are we, where are we going. Medico-Legal Journal, 2014, 82, 57-66.	0.2	1
186	HOT mutation screening in human glioblastomas. Future Science OA, 2015, 1, .	0.9	1
187	Reply to letter to the editor: baricitinib and toxicity is a rare occurrence. Expert Opinion on Drug Safety, 2020, 19, 1371-1372.	1.0	1
188	Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients. Breast Cancer Research and Treatment, 2021, 188, 465-476.	1.1	1
189	Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?. Translational Lung Cancer Research, 2021, 10, 3858-3860.	1.3	1
190	Abstract 2670: Genetic variants in human epidermal growth factor receptor (HER) family gene predict tumor recurrence in breast cancer. , 2012, , .		1
191	Abstract P3-06-31: Patient-derived xenografts accurately predict patient response in breast cancer patients. , 2015, , .		1
192	Use of genetic variants of LMTK3 to predict tumor recurrence in female localized gastric adenocarcinoma.. Journal of Clinical Oncology, 2012, 30, 63-63.	0.8	1
193	Neurolymphomatosis of multifocal peripheral nerve involvement: a case report. Annals of Palliative Medicine, 2022, 11, 2529-2537.	0.5	1
194	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer (LC): Implications for immunotherapy.. Journal of Clinical Oncology, 2016, 34, 11601-11601.	0.8	1
195	Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy. Oncotarget, 2018, 9, 6007-6014.	0.8	1
196	Bella and the blood sample. BMJ: British Medical Journal, 2003, 327, 497-497.	2.4	0
197	AIDS-related cancers, Part I: Kaposi's sarcoma and cervical cancer. Community Oncology, 2005, 2, 507-511.	0.2	0
198	AIDS-related cancers, Part II: Systemic and cerebral lymphomas. Community Oncology, 2006, 3, 34-41.	0.2	0

#	Article	IF	Citations
199	AIDS associated malignancies. Update on Cancer Therapeutics, 2006, 1, 221-234.	0.9	0
200	New therapies for hepatitis infection. Future Virology, 2006, 1, 533-535.	0.9	0
201	Translational review of AIDS-related Kaposi's sarcoma. Update on Cancer Therapeutics, 2007, 2, 53-60.	0.9	0
202	HBV and lymphoma: HIV matters. Aids, 2011, 25, 274-275.	1.0	0
203	Crystals and cancer: good vibrations or bad intentions?. Lancet Oncology, The, 2014, 15, 263-264.	5.1	0
204	Genetic variants and response to cancer treatments. Cancer, 2015, 121, 1735-1736.	2.0	0
205	Artemisia: a divine dart against cancer?. Lancet Oncology, The, 2015, 16, 759-760.	5.1	0
206	Probiotics and cancer: ready for meal time?. Lancet Oncology, The, 2015, 16, 371-372.	5.1	0
207	Response to Cottu, Bozec, Basse, and Paoletti. Journal of the National Cancer Institute, 2021, 113, 344-345.	3.0	0
208	Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer. British Journal of Cancer, 2021, 125, 907-908.	2.9	0
209	Methylation Status of SMURF2 and Correlation with Clinical Parameters in Patients with Multiple Myeloma. Blood, 2008, 112, 4472-4472.	0.6	0
210	Snk/Plk2 Methylation Is a Frequent Event in Patients with Multiple Myeloma. Blood, 2008, 112, 4479-4479.	0.6	0
211	BIK (Bcl2-Interacting Killer) CpG Methylation Status in Multiple Myeloma Patients: a Potential Predictor of Relapsed/Refractory Disease.. Blood, 2009, 114, 2397-2397.	0.6	0
212	Abstract LB-226: Identification of novel kinases modulating ER: new therapeutic targets in breast cancer. , 2010, , .		0
213	Abstract LB-8: Liquid chromatography - mass spectrometry proteomics to monitor the activity of multiple phosphorylation signaling pathways in cancer. , 2012, , .		0
214	Abstract 64: Identification of novel kinases involved in Estrogen receptor-Î± (ERÎ±) signalling and the development of endocrine resistance in breast cancer. , 2012, , .		0
215	Abstract 3794: The role of LMTK3 in breast cancer cell growth and invasion.. , 2013, , .		0
216	Abstract 1606: Global mapping of tyrosine kinase signalling in breast cancer by combined use of RNAi and SILAC quantitative proteomics. , 2014, , .		0

#	Article	IF	Citations
217	Abstract 4213: Evaluation of LMTK3 expression and tumor phenotype in estrogen-dependent colorectal cancer. , 2014, , .		0
218	Abstract 5268: The expression of lemur tyrosine kinase-3 in high grade pediatric tumors. , 2014, , .		0
219	Abstract 1617: Quantification of pancreatic cancer proteome & phosphorylome: Indicates molecular events likely contributing to cancer & activation status of drug targets. , 2014, , .		0
220	The many-faced KSR1: a tumor suppressor in breast cancer. Oncoscience, 2015, 2, 669-670.	0.9	0
221	MicroRNAs associated with small bowel neuroendocrine tumors and their metastases.. Journal of Clinical Oncology, 2016, 34, 11598-11598.	0.8	0
222	Abstract 185: Role of phosphorylation in Lmtk3 activation and its contribution in breast cancer progression. , 2016, , .		0
223	Abstract LB-339: Mutation analysis of cell-free DNA captures heterogeneity of individual circulating tumor cells in metastatic breast cancer. , 2016, , .		0
224	Surgery in combination with peptide receptor radionuclide therapy is effective in metastatic neuroendocrine tumors and is definable by blood gene transcript analysis.. Journal of Clinical Oncology, 2017, 35, e15697-e15697.	0.8	0
225	Enhanced Sensitivity of Lymphoid Cells to Ethanol ADH Acetaldehyde Toxicity; Implications for GDEPT and Adoptive T Cell Therapy. Current Pharmacogenomics and Personalized Medicine, 2018, 16, 118-123.	0.2	0
226	Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report. BMC Pulmonary Medicine, 2022, 22, 54.	0.8	0
227	Developments in paediatric cancer care throughout the COVID-19 pandemic: Lessons from China. The Lancet Regional Health - Western Pacific, 2022, 20, 100398.	1.3	0